Press Release

SoluLinK, Incorporated
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121
Phone: 858.625.0670
Fax: 858.625.0770
solulink@solulink.com 

SoluLinK Appoints David McCarty to Its Board of Directors
San Diego, California, June 6, 2006

SoluLinK, Inc. a leader in biomolecular conjugation products and services for life science, diagnostic, and nanotechnology markets, announced today the appointment of David McCarty to its Board of Directors.

Mr. McCarty is currently the President and CEO of PanCel. He has held senior positions in the health care industry for over 30 years. Most recently, Mr. McCarty was President and CEO of NOVEX, which he successfully merged with Invitrogen (a publicly-traded research products company) in August 1999. He served on the Board of Directors of Invitrogen from August 1999 to August 2004. Prior to joining NOVEX in 1997, Mr. McCarty was the President and CEO of Alexon Biomedical, a medical diagnostics company, which he led to a successful financial turnaround and a profitable strategic sale to Sybron International (now Apogent Technologies) in early 1997. His other professional experience includes senior operating positions at Gen-Probe, Allergenetics, Calbiochem-Behring, Boehringer Mannheim Diagnostics, and Hyland Diagnostics. Mr. McCarty received his B.S. in chemistry from California State University at Northridge and his M.B.A. from California State University at Long Beach.

"It is an honor to have David McCarty join SoluLinK's board. He is a proven leader and brings market savvy and practical business expertise to SoluLinK from his successful experience managing and directing multiple bioscience companies,” stated Steve DeGraw President and Chief Business Officer of SoluLinK. “His knowledge of all aspects of the management of rapidly growing life science companies will be invaluable to SoluLink’s continued growth.

About SoluLinK
SoluLinK is a leader in the development of advanced biological reagents and custom services for the life sciences, diagnostic, and nanotechnology research communities. Specifically, SoluLinK (a privately-held company located in San Diego, California) develops, manufactures, and markets bioconjugation products and services. SoluLink’s proprietary bioconjugation linking chemistry is used to link proteins, oligonucleotides, peptides, and antibodies to each other or to a wide range of surfaces. A rapidly growing application for SoluLink’s linking technology include conjugation of biomolecules to solid surfaces for diagnostic, therapeutic, and/or microarray products. SoluLinK’s proprietary biotinylation reagent ChromaLink® Biotin is one more example of a new product that is helping to enhance the performance of more defined biotin-antibody conjugates used by a wide spectrum of customers. SoluLinK markets these products directly and through distributors/licensing partners, world-wide.

For more information, please contact Solulink directly:

SoluLinK - The Conjugation Company
9853 Pacific Heights Blvd. Suite H,
San Diego, California 92121

Toll Free: 888.625.0670
Phone: 858.625.0670
Fax: 858.625.0770
solulink@solulink.com